Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis.
Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis.
复制标题
静脉注射盐酸尼非卡兰用于预防血液透析肾功能衰竭患者缺血引起的室性快速性心律失常。
DOI：
10.1253/circj.67.898
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
H. Nonogi
中科院分区：
文献类型：
--
作者：
Masafumi Myoishi;S. Yasuda;S. Miyazaki;K. Ueno;I. Morii;K. Satomi;Yoritaka Otsuka;A. Kawamura;T. Kurita;S. Kamakura;H. Nonogi
尿液排泄是新型Ⅲ类抗心律失常药盐酸尼非卡兰（NIF）消除的重要途径。 3 名肾功能衰竭患者正在接受血液透析并接受 NIF 以预防缺血引起的室性快速心律失常。由于 NIF 不需透析，因此需要在相对较低的浓度下调整剂量，并监测 QT 间期。
Excretion in the urine is an important pathway for the elimination of nifekalant hydrochloride (NIF), a novel class III antiarrhythmic agent. Three patients with renal failure were undergoing hemodialysis and receiving NIF for the prevention of ischemia-induced ventricular tachyarrhythmia. Because NIF is not dialyzed, dose adjustment at relatively low concentrations was required, with monitoring of the QT interval.